Immune checkpoint inhibitors as the secondline treatment for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis based on network meta-analysis

Immune checkpoint inhibitors (ICIs) have demonstrated superior clinical efficacy in prolonging overall survival (OS) as the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC), and were recommended by the guidelines.